SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Vaxcyte Reports Q3 2026 Results, Positive VAX-31 Phase 3 Topline Data

Vaxcyte reported third-quarter 2026 financial results and announced positive topline data from the OPUS-1 pivotal Phase 3 trial for VAX-31’s adult indication.

PCVX
SquawkNews Desk 1 updates Updated Nov 04, 2026, 09:14 PM UTC

Story updates

09:14:56 PM UTC
SquawkNews
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Related stories

Great Elm Group Q1 Revenue Drops on Property Sale Timing Great Elm Group reported lower Q1 revenue, citing the timing of property sales. M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC Vaxcyte Q3 Loss Smaller Than Estimates; Plans VAX-31 Filing in H1 2028 Vaxcyte reported a Q3 loss smaller than estimates and plans to file VAX-31 in the first half of 2028. M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC Mercado Libre Q3 Revenue and Financial Income Rise 45% to $10.75 Billion Mercado Libre reported third-quarter net revenue and financial income of $10.75 billion, up 45% year over year. Brazil delivered the strongest growth. M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC Genworth Financial Posts Q3 Net Loss on Closed Block Weakness Genworth Financial reported a third-quarter net loss, citing weakness in its Closed Block segment. M impact | EQUITY | Nov 04, 2026, 10:08 PM UTC B2Gold Reports Q3 Results, Lowers Annual AISC Guidance B2Gold lowered its annual all-in sustaining cost guidance and said it remains on track to achieve production guidance. M impact | EQUITY | Nov 04, 2026, 10:08 PM UTC Eversource Q3 GAAP Earnings Fall 6% to $346 Million M impact | EQUITY | Nov 04, 2026, 10:08 PM UTC